marketed after patent expiration are referred to as biosimilars to indicate they are not identical, but similar products. 1, 3 While generics only require a demonstration of pharmaceutical equivalence by means of a pharmacokinetic comparison in healthy volunteers, biosimilars demand a set of studies on comparative biochemical and analytical characterizations, preclinical and clinical data to assure the differences related to the original product lie within an acceptable range with no clinical implications. Therefore, biosimilarity is based on a comparability exercise whereby unavoidable clinical differences are evaluated and must meet equivalence or non-inferiority criteria. 1, 3 Biosimilars need to comply with different regulatory requirements for market authorization in different sites, which will be discussed here.
International regulatory outlook
Biosimilars are defined as copy versions of an already authorized biological 'innovator' product (or reference product) with demonstrated similarity in physicochemical characteristics, efficacy and safety, based on a comprehensive comparability exercise. According to the World Health Organization (WHO), head-to-head comparisons of a biosimilar candidate against the reference product are mandatory for establishing biosimilarity in biological products. 3 If a copy version of a biological product is developed without the comparability exercise, it should not be labeled as biosimilar, even if it is eventually approved in a country with a less stringent national regulatory authority. 2 These products (which disregarded the comparability exercise) cannot rely on data generated with the reference product and should be licensed through the ordinary processes used in a full licensing application. 3 Many countries have developed specific regulations for market approval of biosimilars. The European Medicine Agency (EMA) is the most advanced regulatory authority in this area, having developed a comprehensive number of legal documents and guidelines, which are often considered a model for other countries. 4 Regulated countries such Japan, Canada and Australia follow a similar approach to EMA and have published their requirements. In 2009, WHO has also issued guidelines to provide globally acceptable principles for licensing biological products that claim to be similar to approved reference products. 3 WHO guidelines also highlighted that several important issues associated with biosimilars need to be defined by the national authorities, including intellectual property issues, interchangeability, labeling and prescribing information. 3 In the US, a piece of legislation referred to as the Biologics Price Competition and Innovation Act (BPCI Act), also called the Biosimilar Act, was passed in 2010. 5 This legislation has provided the US Food and Drug Administration (FDA) the legal framework to develop its guidelines on the subject that started to be released in 2012. 6 Despite the differences between regulations and guidelines in different countries, there is a solid convergence on some requirements for approval of biosimilars, which is interesting to highlight:
(1) A complete dossier on manufacturing and quality; (2) Comparative non-clinical and clinical studies;
(3) Studies designed with sensitivity to detect differences, and planned as non-inferiority or equivalence with predefined margins; (4) Nonclinical and clinical immunogenicity studies; (5) Postmarketing risk management plan and risk minimization strategies.
The Brazilian regulation
In December 2010, the National Health Surveillance Agency (ANVISA), responsible for drug regulation in Brazil, has issued a revised directive for biologic products ('Resolution of the board of directors' RDC 55/2010), specifying the minimum requirements to submit an application for registration of new and follow-on (copies) biologic products. 7 Considered within the scope of the document are therapeutic proteins, monoclonal antibodies, vaccines, therapeutic serum, blood derivatives, tissue extracts and some living organisms. It contains the basic principles enumerated above, but also includes some provisions viewed with some concerns since they are not completely aligned with international trend.
In the ANVISA terminology, two terms are used: 'new biologic product,' which is a new biologic entity not yet registered; and 'biologic product,' which refers to copies or follow-on products containing an active substance already registered by the agency. The obvious intention with this nomenclature is to make clear that biosimilarity is not necessarily a precondition for the approval of copy biologic products. Not withstanding using the denomination of 'biologic products' for copies, whether they are similar or not, is confusing and therefore is considered inappropriate.
According to Brazilian regulation, the applicant may submit a 'biologic product' (copy) via two possible pathways: (a) by comparability with the reference product, resulting in a true biosimilar; or (b) via standalone application (via de desenvolvimento individual), with a reduced dossier and resulting in a nonbiosimilar copy. This individual development pathway introduces a more permissive approach in which the copy product does not require a full comparison with the original one. Therefore, this alternative pathway might approve products with an unknown degree of dissimilarity (Table 1 ).
In the Brazilian regulations, there is no minimum period of time between the authorization of the biological innovator and the request for a biosimilar license, that is, there is no relation to the patent issue. 8 Table 2 , there is no discrimination on nonproprietary names for biosimilars and reference. This differentiation is needed to provide the prescribing physician the option to designate the product to be dispensed and, perhaps more importantly, to ensure the necessary traceability for safety assessments. As emphasized by the FDA, the consequences of immunogenicity of these large biotherapeutical proteins in patients with autoimmune disease may vary widely and calls for an effective pharmacovigilance, even with the initial expectation of low risk. 10 Interchangeability is the condition whereby two or more pharmaceutical products can be changed or even alternated during the treatment, without any compromise to the efficacy and safety. Interchangeability usually authorizes automatic substitution, meaning that the medical prescription can be changed to any interchangeable product without the participation of the treating physician. Basically, it is a regulatory definition. 11 The notion of interchangeability is accepted with few exceptions for synthetic drugs and small peptides coined as generics because active substances are identical. Nonetheless, biosimilars, nonbiosimilar copies, and the reference products do not have identical active substance and in principle should not be considered interchangeable. FDA has established clear rules on this issue, demanding efficacy and safety data showing that no additional risks are incurred by the patient when comparing the exchange between two products with the exclusive use of the innovative product. 5 EMA, on the other hand, does not have the authority to designate a biosimilar as interchangeable and the decisions rest with each member state in the EU. The concept of interchangeability in Europe is 'the medical practice of changing one medicine for another that is expected to achieve the same clinical effect in a given clinical setting and in any patient on the initiative, or with the agreement of the prescriber.' Many of the European countries, such as the UK, Finland, Denmark, and Norway, have supported physician-led switching. 12 Unfortunately, in many countries, Brazil among those, interchangeability had not been defined by a regulatory agency and thus left a perilous gap in this matter. A recent ANVISA clarification note states that interchangeability is more directly related to clinical practice than to regulatory status. 13 In addition, it emphasizes medical evaluation as essential in the case of substitution and interchangeability of biosimilar products and their comparators, but in the same paragraph, states that multiple exchanges between these products is not acceptable, as traceability and monitoring of use are very difficult in these cases. Therefore, the current regulation delegates this complicated decision to payers or physicians. This situation can increase the risk of physicians' conflicts of interest and pressure by large-profit health insurance providers including medical cooperatives and private health management organizations. Physicians who are part of a medical cooperative are often pressured by the directory board to prescribe the cheapest medicine and procedure on the grounds that they could be undermining the profit of all coworkers. Physicians who provide services to health insurance companies can lose their accreditation if they are considered big spenders when advocating against a cheaper biosimilar. Physicians linked to public health services have job stability and can easily prescribe all the approved drugs in the country according to the regulation of each condition. However, the pharmaceutical companies have varied the price of biologics in order to receive the label of first-choice medication in the clinical protocols and therapeutic guidelines of the government. Thus, the difference of values between original drugs and biosimilars is not at all clear. There are obvious risks if the payers' decision is only based on the product's approval by the regulatory authorities. As the editorial from Minghetti and colleagues points out, 'When the prescription of a biosimilar arises from a payer's policy, it is not substitution in the proper sense, and if it constitutes an administrative limit to the prescriber's freedom, it should have a different name, such as a "constrained prescription".' 14 In the private sector, the pressure on the physician to use biosimilars was felt early, especially within medical cooperatives. In the public sector, we have recently seen a government move to create a cost-based hierarchy of biologic prescriptions. A technical note by the Ministry of Health 15 was published at the beginning of this year proposing two lower-cost products as the first-line prescription for rheumatoid arthritis. This initiative did not address the biosimilar product and was received under a great discussion. Only 2 months later, another note 16 preserved the prescription order of the biologics but now with the necessary flexibility to use any approved drug since justification is presented. In addition, when indicating what product should be used without studies to support this decision, physicians expose themselves to be held accountable for any treatment-related failures or complications.
The first biosimilar approved by the comparative development pathway in the country, and at present the only monoclonal antibody in the field of rheumatology, is the biosimilar infliximab, Remsima® (Pfizer), which was approved for all eight indications of the original licensed biologic product. ANVISA RDC 55/2010 addresses criteria for extrapolation, which cannot be granted via standalone application, but it does not solve all the controversies involved among different indications. There is still a need for more detailed regulation on this issue. Another concern is when the prescribing physician is usually not notified on what drug was delivered for the patients in the public sector, except when the patients receive their drug administration at an assisted (immunobiological) therapy center where the prescribing physician works or when this center shares information with the physician.
It is necessary to pay attention to the increasing knowledge on technical and regulatory aspects of biosimilars, especially in Brazil, where there is either a huge private market for the use of biological products, or a great cost to the government that subsidizes these medications free of charge within the public health system for several diseases.
The Brazilian Society of Rheumatology is developing the official positioning regarding biosimilars, in order to motivate more definite positioning from ANVISA.
Currently, biologics consume 43% of the Ministry of Health's resources with medicines, about US$1.2 billion per year. 17 Cost reduction is the major motivator of biosimilar development, but the proportion of savings is not comparable to the magnitude seen with generics. 18 Moreover, there are no clear estimates of what will be the decrease in the value of these medicines in Brazil.
Conclusion
The directive for licensing biosimilars published by the Brazilian Regulatory Agency in 2010 is very much aligned with the principles seen on the WHO norms and standards for the evaluation of similar biotherapeutic products. However, it includes some controversial changes such as nomenclature (naming the copies as produto biológico, avoiding the use of the term biosimilar), and the addition of an alternative pathway of approval not based on the comparability exercise.
Designating approved copies of biologic products as biosimilars after the comparability exercise has been well received by most regulatory authorities and the academic world. ANVISA may find an opportunity to revise its regulation and also adopt this expression. It has been generally recognized that many important issues associated with biosimilars need to be defined by the national authorities; we therefore emphasize the need for regulation on the topics of labeling, extrapolation and interchangeability. We believe the absence of a governmental position on these issues threatens the good practice of physicians and the health of patients, and is worsened by the concerns of traceability. The development of biosimilars backed by proper regulation can provide cost savings while also preserving clinical effectiveness and safety for the patients.
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